Genoptix, Inc. entered into a definitive agreement to acquire PDx Business of Rosetta Genomics Ltd. (NasdaqCM:ROSG) for $1 million on February 27, 2018. Under a separate merger agreement, Genoptix will purchase the remainder of Rosetta Genomics’ business for $8 million in cash, subject to certain adjustments. Upon closing of the merger, trading in shares of Rosetta Genomics on the Nasdaq Capital Market will cease, and Rosetta Genomics will become a wholly owned subsidiary of Genoptix. The transactions have been unanimously approved by the Board of Directors of Rosetta Genomics and Genoptix. The definitive agreement to acquire PDx Business is expected to close by the end of this week. Cantor Fitzgerald, L.P. is serving as financial adviser to Rosetta Genomics on this transaction. Genoptix, Inc. completed the acquisition of PDx Business of Rosetta Genomics Ltd. (NasdaqCM:ROSG) on March 2, 2018.